Jason Beaubien

The U.S. Food and Drug Administration's decision to temporarily halt the use of the Johnson & Johnson COVID-19 vaccine is having ramifications globally.

Soon after U.S. regulators paused the use of the J&J single-dose vaccine, health authorities in many European countries and in South Africa announced that they were also putting it on hold.

Rare, but potentially fatal blood clots linked to the AstraZeneca vaccine has lead to several countries limiting its use in young people. It's a vaccine many countries are depending on.

The European Medicines Agency says there is a possible link between the AstraZeneca COVID vaccine and rare blood clots.

The island nation is going it alone. No contracts with big drug makers, no support from WHO's vaccine program. If successful, Cuba will be the first producer of a vaccine in Latin America.

Some countries have made great strides in vaccinating their populations, but much of the world has made hardly any headway. Countries with excess vaccine stockpiles could loan doses to those in need.

A rare blood clotting condition has occurred in some people after receiving the AstraZeneca COVID-19 vaccine. If the new research is correct, it could mean that blood clots could be easily treated.

"Too many people are coming here right now," Mayor Dan Gelber said on Saturday as he proclaimed a 72-hour state of emergency to address swelling crowds and fears of fueling a surge in COVID-19 cases.

The agency's conclusion comes as the Biden administration announced it would send AstraZeneca vaccines to Canada and Mexico.

More European countries are suspending use of the AstraZeneca COVID-19 vaccine after reports that some recipients developed blood clots. The vaccine is not authorized in the United States.